PURE Bioscience (PURE Bioscience) Cash And Cash Equivalents : $0.56 Mil (As of Jan. 2024)

View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Cash And Cash Equivalents?

PURE Bioscience's quarterly cash and cash equivalents increased from Jul. 2023 ($1.10 Mil) to Oct. 2023 ($1.44 Mil) but then stayed the same from Oct. 2023 ($1.44 Mil) to Jan. 2024 ($0.56 Mil).

PURE Bioscience's annual cash and cash equivalents increased from Jul. 2021 ($2.39 Mil) to Jul. 2022 ($3.39 Mil) but then declined from Jul. 2022 ($3.39 Mil) to Jul. 2023 ($1.10 Mil).

PURE Bioscience Cash And Cash Equivalents Historical Data

The historical data trend for PURE Bioscience's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PURE Bioscience Cash And Cash Equivalents Chart

PURE Bioscience Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.40

3.84

2.39

3.39

1.10

PURE Bioscience Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1.49	0.78	1.10	1.44	0.56

PURE Bioscience Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

PURE Bioscience (OTCPK:PURE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

PURE Bioscience Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

PURE Bioscience (PURE Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019

Website

https://www.purebio.com

PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.

Executives

Robert F Bartlett	director	9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner	director	9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee	director	1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall	director	9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor	director	13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno	director	35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen	director	1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers	officer: Chief Operating Officer	1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert	director, officer: Chief Executive Officer	1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen	director	1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field	director	9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc	10 percent owner	325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott	officer: Vice President, Finance	1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis	director	1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno	director	1725 GILLESPIE WAY, EL CAJON CA 92020